Dendrimer-FSH Conjugation Service

Dendrimers bind to FSH to selectively target the selective FSHR for the treatment of ovarian cancer. CD BioSciences has advanced facilities and experienced scientists to provide high quality FSH binding to dendrimers.

Introduction into FSH

Follicle-stimulating hormone (FSH) is a glycoprotein heterodimer of 35.5 kDa in size, synthesized and secreted by anterior pituitary gonadotropic cells and composed of two polypeptide units, alpha and beta. FSH is used to regulate development, growth, pubertal maturation, and reproductive processes in the body. As a glycoprotein peptide hormone, FSH and luteinizing hormone (LH) work in concert in the reproductive system.

FSH and Ovarian Cancer

Ovarian cancer is the fifth leading cause of cancer-related death and the deadliest malignancy in gynecology. Current modalities used for ovarian cancer treatment include surgery and chemotherapy, with a combination of cytoreductive surgery and chemotherapy being the conventional approach for treating patients with advanced ovarian cancer. Although most patients have an initial response to first-line drug therapy, most patients will experience recurrence. Furthermore, drugs indicated for ovarian cancer, such as paclitaxel and cisplatin, like other chemotherapeutic agents, are often accompanied by severe side effects due to their non-specific biodistribution to healthy tissues. There is therefore a great need to design therapies that can selectively target tumor cells to reduce systemic side effects and improve the therapeutic index of most chemotherapeutic agents.

In the ovary, FSH plays an important role in the maturation of immature follicles to mature follicles by acting as a ligand that binds to and is activated by the follicle-stimulating hormone receptor (FSHR). Immature follicles are the least mature follicles in the ovary and do not express FSHR. Therefore, drug vectors that selectively target FSHR may protect immature follicles from the toxic effects of chemotherapy and potentially allow women with ovarian cancer to maintain fertility.

Dendrimer-FSH Conjugation

Approximately 95% of newly developed potential therapeutic agents have poor pharmacokinetics, and therefore there is an urgent need to develop an effective delivery system that targets tumor cells without affecting healthy tissue. Targeting of FSHR can be achieved using peptide sequences modeled after the FSH binding domain, with the amino acid 33-53-derived peptide (FSH33) exhibiting the strongest binding affinity for FSHR and often used as a targeting ligand for ovarian tumor tissues.

In the past decades, nanotechnology has provided an effective platform for targeted drug delivery to enable selective delivery of drugs to target tissues and organs. Nanomaterials used for targeted drug delivery include materials such as liposomes, micelles, and dendrimers.

As one of the most attractive drug carriers, dendrimers are hyperbranched structures with a central core and flexible surface function. When dendrimers bind to FSH, they can more effectively target tumor tissue with FSHR without affecting the surrounding healthy immature follicles.

Overview of the preparation of FSH33-targeted G5 PAMAM dendrimer conjugates. (Modi DA, et al., 2014)

Our Services

As a fast growing and leading global provider of scientific research services and solutions, CD BioSciences offers you dendrimer-FSH conjugation services. We are committed to meeting all your detailed requirements and guarantee that all deliverables are subjected to rigorous quality testing.

Service Process

CD BioSciences is committed to helping our customers meet the growing and evolving demand for dendrimers products. We offer a wide range of services related to dendrimers and ensure quality and reliability of results as well as on-time delivery. If you are interested in our services or have any additional questions, please feel free to contact us, we are happy to hear from you and look forward to working with you.

Reference

1. Modi DA.; et al. Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells. Nanoscale.2014, 6: 2812-20.